AstraZeneca COVID-19 vaccine is effective against the Brazilian variant (P1), indicates preliminary data from a study led at the University of Oxford, according to information from Reuters, via a source with knowledge of the study.

The study shows that the immunizer will not require modification in order to protect against the variant, the source told the news agency.

The source did not give the exact efficacy of the vaccine against the Brazilian variant, but said the complete results are likely to be published still in March.